| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10965563 | Vaccine | 2014 | 6 Pages |
Abstract
This study supports that PPV23 does not provide any relevant benefit against AMI in the general population over 60 years, as in primary as well as in secondary prevention, although it is underpowered to exclude a small benefit of vaccination against rare outcomes.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
O. Ochoa-Gondar, A. Vila-Corcoles, T. Rodriguez-Blanco, C. de Diego-Cabanes, I. Hospital-Guardiola, M. Jariod-Pamies, on behalf of EPIVAC Research Group on behalf of EPIVAC Research Group,